Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic SyndromesGuillermo Garcia-Manero, Valeria Santini, Antonio Almeida, et al.
Hemasphere|April 20, 2026
APL-like subset within <i>NPM1</i>-mutated AML: A distinct immunophenotype correlating with early vascular complicationsFrancesco Mannelli, Francesca Crupi, Sara Bencini, et al.
The Lancet. Haematology|February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther N Oliva, Caterina Alati, Valeria Santini, et al.
British Journal of Haematology|August 26, 2025
Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 studyElisa Lucchini, Nicola Vianelli, Ugo Consoli, et al.
American Journal of Hematology|July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systemsRena Buckstein, Enrico Balleari, Richard Wells, et al.
Cancer Medicine|March 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization ExperienceStefania Oliva, Marina Martello, Elona Saraci, et al.
Blood|August 10, 2019
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Alfonso Piciocchi, Anna Candoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Esther Natalie Oliva, Marta Riva, Pasquale Niscola, et al.
Annals of Hematology|March 15, 2019
Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian studyElisa Cannizzo, Maddalena Raia, Maria Stefania De Propris, et al.
Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Pageof 15